This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
Respimat, commonly referred to as Respimat SMI (SMI indicates "Soft Mist Inhaler") is an advanced drug delivery device in comparison to MDIs (metered-dose inhalers) or DPIs (dry powder inhalers) used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the U.S. with a variety of their products, such as Spiriva (tiotropium bromide) and Combivent (ipratropium bromde/albuterol).
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|